Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarpogrelate versus clopidogrel for peripheral atherosclerosis in ischemic stroke patients
KCT0012594Phase 4Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ischemic stroke and arteriosclerosis obliterans comparing Aspirin + sarpogrelate with Aspirin + clopidogrel (2 arms). Primary endpoint: Ankle-brachial index at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
sarpogrelateclopidogrelaspirin
03
Conditions
ischemic strokearteriosclerosis obliterans
Beyond the preview
Go deeper on KCT0012594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012594.